Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy

Phase II Study of Single-Agent Arsenic Trioxide for the Front-Line Therapy of Acute Promyelocytic Leukemia

(2011) Ardeshir Ghavamzadeh et al.   JOURNAL OF CLINICAL ONCOLOGY

Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710

(2010) B. L. Powell et al.   BLOOD

Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up Data

(2010) Vikram Mathews et al.   JOURNAL OF CLINICAL ONCOLOGY

Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia?

(2010) David Grimwade et al.   LEUKEMIA RESEARCH

Comparison of Clinical Outcomes of Patients with Relapsed Acute Promyelocytic Leukemia Induced with Arsenic Trioxide and Consolidated with Either an Autologous Stem Cell Transplant or an Arsenic Trioxide–Based Regimen

(2009) Rajasekar Thirugnanam et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy

(2009) David Grimwade et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia

(2009) J. Hu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

(2008) M. A. Sanz et al.   BLOOD

Acute promyelocytic leukemia: from highly fatal to highly curable

(2008) Z.-Y. Wang et al.   BLOOD

Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin

(2008) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY